[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatitis-a\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatitis-a":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,146,168,194],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100633339","comparative-evaluation-of-oral-ursodeoxycholic-acid-in-reducing-bilirubin-levels-among-patients-with-acute-viral-hepatitis-100633339",false,"NCT07525401","Comparative Evaluation of Oral Ursodeoxycholic Acid in Reducing Bilirubin Levels Among Patients With Acute Viral Hepatitis","AVH","Inclusion Criteria:\n\n* All patients of either gender\n* aged \\>18 years to 50 years with acute viral hepatitis are included\n\nExclusion Criteria:\n\n* Patients having Hepatitis B, C\n* hepatocellular carcinoma\n* primary biliary cholangitis\n* choldocholithiasis\n* patients having normal bilirubin levels with AVH were excluded.","ALL","18 Years","50 Years",{"count":20,"type":21},88,"ESTIMATED","INTERVENTIONAL",[24],"NA","Hepatitis is an inflammatory condition of the liver that has emerged as a significant global health concern due to its widespread prevalence.\n\nData on ursodeoxycholic acid in acute viral hepatitis remain limited. Some studies suggest its positive effect in cholestatic phase of viral hepatitis. UDCA may reduce cholestatic symptoms like jaundice and pruritus potentially shortening hospital stay and improving patient outcomes. However, robust clinical data supporting its routine use in acute viral hepatitis are lacking, and current treatment remains largely supportive. Given the high burden of acute viral hepatitis in our region and the potential for UDCA to improve cholestatic phase of AVH there is a clear need for well-designed clinical studies evaluating its therapeutic role. This study aims to evaluate the role of oral ursodeoxycholic acid in biochemical recovery of patients with acute viral hepatitis. If positive role is confirmed, it will be incorporated in standard treatment and if no role is found unnecessary use will be discouraged.\n\nNull Hypothesis (H₀):\n\nOral ursodeoxycholic acid has no significant effect on the bilirubin levels of patients with acute viral hepatitis.\n\nH₀: There is no statistically significant difference in bilirubin levels between patients receiving ursodeoxycholic acid and those receiving supportive care alone.\n\nAlternative Hypothesis (H₁):\n\nOral ursodeoxycholic acid reduces bilirubin levels in patients with acute viral hepatitis. H₁: There is statistically significant difference in bilirubin levels between patients receiving ursodeoxycholic acid and those receiving supportive care alone.",[27,28],"Hepatitis A","Hepatitis E Virus Infection",[30,31,32,27,33],"Acute viral hepatitis","Ursodeoxycholic acid","UDCA","Hepatitis E","NOT_YET_RECRUITING","2026-04-10",{"date":37,"type":38},"2026-04-13","ACTUAL",{"date":40,"type":21},"2026-04",{"date":42,"type":21},"2026-10",{"name":44,"class":45},"Combined Military Hospital, Pakistan","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":117,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":145},"100620537","risk-assessment-of-community-spread-of-multiple-endemic-infectious-diseases-in-a-one-health-perspective-100620537","NCT07358910","Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","RACSMEI","Inclusion Criteria:\n\n* Residency in the village for more than 6 months;\n* Age between 2 and 75 years old at the time of inclusion;\n* For adults: provision of written consent;\n* For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;\n\nExclusion Criteria:\n\n* Unable to understand or consent;\n* Under guardianship or deprived of liberty;\n* Medical conditions that impede survey participation;\n* Refusal to participate in the study.",true,"2 Years","75 Years",{"count":57,"type":21},10000,"OBSERVATIONAL","RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.\n\nRACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.\n\nMathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.",[61,62,63,64,65,66,67,68,69,33,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,27,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116],"Dengue","Chikungunya","Zika Virus Infection","Japanese Encephalitis","West Nile Virus","Tick-borne Encephalitis (TBE)","Severe Fever With Thrombocytopenia Syndrome","Nipah Virus Infection","Hantavirus Infections","Brucellosis","Q Fever","Leptospirosis","Melioidosis","Influenza A and B","Malaria","Yellow Fever","Mayaro Fever","Usutu Virus Infection","Oropouche Fever","Rift Valley Fever","Arenavirus Infections","Measles","Mumps","Rubella","Human Papilloma Virus (HPV)","Rotavirus Disease","Pertussis","Diphteria","Tetanus","Varicella","Norovirus Infections","Enterovirus","Adenovirus","Rhinovirus","Parvovirus","Respiratory Syncytial Virus (RSV)","Cytomegalovirus","Epstein Barr Virus","Salmonella Typhi","Vibrio Cholerae","Legionella Pneumophila Pneumonia","Mycoplasma","Chlamydia","Lymphatic Filariasis","Toxoplasma Gondii","Giardiasis","Entamoeba Histolytica","Leishmaniasis","Strongyloides Stercoralis Infection","Ascaris Lumbricoides","Trichuris Trichiura","Clonorchis Sinensis","Opisthorchis Viverrini","Schistosomiasis","Streptococcus Pneumoniae","Meningitis",[118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134],"Infectious disease","One Health","Population-based survey","Nationally representative survey","Seroepidemiology","Multiplex serology","Seroprevalence","Vector-borne diseases","Zoonoses","Vaccine-preventable diseases","Neglected tropical diseases","Transmission dynamics","Force of infection","Mathematical modelling","Spatial epidemiology","Precision public health","Cambodia","RECRUITING","2026-01-14",{"date":138,"type":38},"2026-01-22",{"date":140,"type":38},"2025-12-18",{"date":142,"type":21},"2027-09-30",{"name":144,"class":45},"Institut Pasteur du Cambodge",1,{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":53,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":167},"100618994","the-five-year-antibody-persistence-after-immunization-with-ipv-mmr-and-hepa-l-vaccines-100618994","NCT07338851","the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines","Evaluation on the Persistence of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell), Combined Live Attenuated Measles, Mumps and Rubella Vaccine and Freeze-dried Live Attenuated Hepatitis A Vaccine in Chinese Children: Up to 5 Years of Follow-up","Inclusion Criteria:\n\n* Participants in the NCT04638985 or NCT04636827, and who have completed the vaccination of designated batch numbers of sIPV, MMR or HepA-L vaccines;\n* The time window from the day of enrollment to the date when the participants received the fourth dose of sIPV vaccine, the second dose of MMR vaccine, or the first dose of HepA-L vaccine was 60 to 66 months.\n* The informed consent form shall be signed by the participant or his\u002Fher legal guardian and dated.\n\nExclusion Criteria:\n\n* None.",{"count":154,"type":21},600,"This study evaluated the antibody persistence of Chinese children five years after they received four doses of sIPV, two doses of MMR vaccine and one dose of HepA-L vaccine.",[157,82,84,83,27],"Polio","2026-01-04",{"date":136,"type":38},{"date":161,"type":21},"2026-01-30",{"date":163,"type":21},"2027-12-31",{"name":165,"class":166},"China National Biotec Group Company Limited","INDUSTRY",6,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":27,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":175,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":4},"100588558","immunity-with-acute-hepatits-a-100588558","NCT06942962","Immunity With Acute Hepatits A","Assessment of Lymphocyte Subset Functions in Children Admitted to Assiut University Children Hospital With Acute Hepatitis A Infection","Inclusion Criteria:\n\n* Children aged 1-15 years\n* Confirmed diagnosis of acute hepatitis A infection (positive anti-HAV IgM)\n* Admitted to the hospital for management of acute hepatitis A\n* Parental\u002Fguardian consent and child assent (where appropriate) obtained\n\nExclusion Criteria:\n\n* Known pre-existing liver disease or chronic hepatitis\n* Immunodeficiency disorders or current immunosuppressive therapy\n* Coinfection with other hepatotropic viruses (HBV, HCV, HEV)\n* Severe malnutrition\n* Recent blood transfusion (within 3 months)","1 Year","15 Years",{"count":178,"type":21},50,"Hepatitis A Virus (HAV) is a public health concern in Egypt, especially among children. Historically highly endemic, recent studies suggest a changing epidemiology. While improved socioeconomic conditions have reduced its spread, HAV remains prevalent, with over 50% of Egyptians exposed by age 15. Infection is often asymptomatic or mild in children but can be more severe with age. Prevention relies on improved sanitation and hygiene, with vaccin and recov",[27,181],"Hepatitis A Virus",[183,184],"Immunity with hepatitis A in children","Lymphocyte subset function in hepatitis A","2025-04-17",{"date":187,"type":38},"2025-04-24",{"date":189,"type":21},"2025-10-01",{"date":191,"type":21},"2026-11-01",{"name":193,"class":45},"Assiut University",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":53,"sex":16,"minAge":201,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":22,"phases":204,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":217},"100551473","phase-4-phase-iv-study-of-concomitant-administration-of-the-sipv-and-hepa-100551473","NCT06460545","Phase IV Study of Concomitant Administration of the sIPV and HepA","Phase IV Study of Evaluating Immunogenicity and Safety of Concomitant Administration of Sabin-strain-based Inactivated Poliovirus Vaccine (Vero Cells) and Freeze-dried Live-attenuated Hepatitis A Vaccine or Inactivated Hepatitis A Vaccine","Inclusion Criteria:\n\n* Age Requirement: Children aged 4 months at the time of enrollment\n* Vaccination Requirement: volunteers have already taken administration 2 doses of sabin-strain-based inactivated poliovirus vaccine (produced by IMBCAMS), and have not yet been injected with the third dose containing poliovirus antigen.\n* Provision of Legal Identification: Volunteers and their legal guardians or appointed representatives must provide valid legal identification documents.\n* Informed Consent: Legal guardians or appointed representatives of volunteers must have the capacity to understand the informed consent document and the research process, voluntarily participate, and sign the informed consent form.\n* Adherence: Legal guardians or appointed representatives of volunteers must be able to comply with the requirements in the study as well as complete relevant visits on time.\n* Birth condition: Full-term birth (37\\~42 gestational weeks) and normal birth weight (no less than 2500g).\n* Temperature Requirement: Axillary body temperature prior to vaccination is less than 37.3°C.\n\nExclusion Criteria:\n\n* Health Requirement: Volunteers cannot meet health requirements through physical examinations.\n* History of Related Illness: Volunteers have a history of developing Hepatitis A, poliomyelitis, or immunodeficiency.\n* Birth Condition: Volunteers have a history of abnormal labor stage, asphyxia, nervous system damage, or clinically confirmed pathologic jaundice。\n* Allergic History: Volunteers have a history of allergies to any component of the investigational vaccine (e.g., aluminum hydroxide), any history of vaccine allergies, suspected allergies, or any other severe adverse reactions.\n* Vaccine History: Volunteers received any inactivated vaccines or subunit vaccines within 7 days (including the 7th day) prior to vaccination with the investigational vaccine, or any other live attenuated vaccines within 14 days (including the 14th day) prior to vaccination.\n* Acute Illness: Volunteers have experienced acute illnesses (e.g., fever) within 3 days prior to vaccination with the investigational vaccine.\n* Neurological and Mental Health: Volunteers have a history of seizures, convulsions, cerebral palsy, epilepsy, mental illness, or a family history of such conditions.\n* Health Conditions: Volunteers have known congenital abnormalities, developmental disorders, genetic defects, or severe malnutrition, among other conditions.\n* Coagulation Abnormalities: Volunteers have a history of coagulation disorders (e.g., coagulation factor deficiency, coagulation disorders).\n* Infectious Diseases: Volunteers have infectious diseases that may affect the study, such as human immunodeficiency virus (HIV) infection, hepatitis, and tuberculosis.\n* Special Condition: Volunteers who could not tolerate venipuncture, or had a history of needle and blood sickness.\n* Organ Removal History: Volunteers have a history of organ removal (e.g., thyroid, pancreas, liver, spleen).\n* History of Blood Products: Volunteers have a history of loss of blood, blood transfusion, the use of adjuvant therapies, or immunoglobulin within 3 months prior to vaccination.\n* Immune Therapy: Volunteers have received immune-enhancing or immune-suppressing therapy within the last 3 months (continuous oral or intravenous administration for more than 14 days) prior to vaccination.\n* Participation in Other Clinical Studies: Volunteers are currently or have plans to participate in other clinical studies before enrollment.\n* Investigator's Discretion: The final exclusion criterion is the investigator's discretion to determine whether a volunteer is suitable for participation in the study.","4 Months",{"count":203,"type":21},2000,[205],"PHASE4","This study is a randomized, open-labeled phase IV clinical trial to evaluate the immunogenicity and safety of concomitant administration of sIPV and HepA-L or HepA-I in children aged 18 months. The primary immunogenicity endpoints in all groups are the seroconversion rates of type I, II, and III anti-poliovirus neutralizing antibodies and the seroconversion rate of anti-hepatitis A virus antibodies 30 days after the final administration. The secondary immunogenicity endpoints are (1) the GMT\u002FGMC of type I, II, and III anti-poliovirus neutralizing antibodies as well as the anti-hepatitis A virus antibodies 30 days after the final administration; (2) the seropositive rates of the anti-hepatitis A virus antibodies 30 days after the final administration; (3) the GMFI of type I, II, and III anti-poliovirus neutralizing antibodies as well as the anti-hepatitis A virus antibodies 30 days after the final administration. The secondary safety endpoints are the incidence of adverse events (AEs) within 30 minutes after each injection, the incidence of solicited local and systematic AEs in the period of solicitation after each injection, the incidence of unsolicited AEs in 30 days after each injection, the incidence of AEs in 30 days after each injection, and the incidence of serious adverse events in 6 months after administrations.",[157,27],"2024-06-11",{"date":210,"type":38},"2024-06-14",{"date":212,"type":21},"2024-06-15",{"date":214,"type":21},"2027-12-15",{"name":216,"class":45},"Institute of Medical Biology, Chinese Academy of Medical Sciences",3]